Exhibiting at FOOD INGREDIENTS CHINA 2025

ABbiotek Health, a division of AB Biotek and part of the Associated British Foods (ABF) Group, is a biotechnology-driven health and wellness company based in London, United Kingdom. Leveraging advanced yeast-based science, the company focuses on the development and commercialization of proprietary postbiotics and bioactives that deliver clinically supported health benefits. With a science-led approach, ABbiotek Health is redefining preventive healthcare through the microbiome and metabolic pathways.

Core Business

ABbiotek Health specializes in research, development, and commercialization of postbiotic and yeast-derived dietary supplements. Their core product lines include:

• Postbiotic Solutions:

  • Postbiotic Immune: Supports immune defense and resilience.
  • Postbiotic Metabol: Targets metabolic health and energy regulation.
  • Postbiotic Digestive: Enhances gut health and microbiome support.

• Yeast-Derived Bioactives:

  • ABB C1® and ABB C22®: Inactive whole-cell yeast with clinical evidence supporting metabolic health benefits.
  • Arthelio®: A unique combination for cardiovascular health.
  • adiDAO®: A novel solution targeting histamine metabolism and inflammatory modulation.
  • adiDAO® Microencapsulated: Enhanced stability formulation for functional food applications.

These ingredients are available as finished dietary supplement solutions and as raw materials for food and beverage applications.

Specialization and Unique Value Proposition

ABbiotek Health stands at the forefront of postbiotic innovation, offering unique yeast-based ingredients that are shelf-stable, non-GMO, vegan-friendly, and supported by scientific and clinical validation. Unlike traditional probiotics, postbiotics from ABbiotek do not require refrigeration, have no risk of translocation, and offer consistent efficacy and scalability in manufacturing.

The company’s proprietary technology platform allows it to extract and stabilize specific yeast strains that modulate key biological functions such as histamine breakdown, cardiovascular resilience, metabolic balance, and immune regulation.

Financial and Market Performance

As a subsidiary of the publicly traded Associated British Foods Group (LSE: ABF), ABbiotek Health benefits from the backing of a conglomerate with £19.7 billion in annual revenue (FY 2023). While specific revenue figures for ABbiotek Health are undisclosed, its rapid expansion in the nutraceutical and functional food markets is well-aligned with the global postbiotics industry, which is forecasted to grow at a compound annual growth rate (CAGR) of over 10% through 2028.

Key market traction has been observed in:

• North America: Rising demand for immune and gut health supplements.
• Europe: Preference for vegan, non-GMO and sustainable ingredients.
• Asia-Pacific: Growth in metabolic and cardiovascular health supplements.

Target Markets

ABbiotek Health serves:

• Nutraceutical Manufacturers: Companies looking to enhance their portfolios with clinically-backed, next-generation ingredients.
• Functional Food and Beverage Brands: Formulators in need of stable, bioactive ingredients for on-the-go formats and shelf-stable applications.
• Pharmaceutical and Medical Nutrition Providers: Clients seeking novel, mechanism-based approaches for chronic condition support.

Operational Capabilities

• Global R&D Infrastructure: ABbiotek maintains research labs across the UK, US, and Asia, collaborating with universities and clinical research partners.
• Clinical Evidence Portfolio: Supports ingredient efficacy with human clinical trials, in-vitro and in-vivo data.
• Formulation Services: Provides clients with technical support for integration into softgels, capsules, powders, beverages, and functional foods.
• Regulatory Compliance: Products meet global regulatory standards, including EU Novel Food approvals and GRAS status in the United States.

Certifications and Compliance

ABbiotek Health adheres to globally recognized quality and safety systems, including:

• ISO 9001 and ISO 22000 Quality Management Systems
• GMP (Good Manufacturing Practices)
• GRAS (Generally Recognized as Safe) status for several ingredients
• Non-GMO, Vegan, and Allergen-Free certifications for core products
• EU and US regulatory filings for novel ingredients and structure-function claims

Major Achievements

• Launch of adiDAO®, the world's first postbiotic targeting diamine oxidase (DAO) activity, addressing histamine intolerance.
• Publication of peer-reviewed clinical trials supporting ABB C1® and ABB C22® in metabolic health.
• Strategic partnerships with ingredient distributors and finished product brands in over 30 countries.
• Recognized in NutraIngredients Awards and Vitafoods Innovation Zones as a postbiotic innovator.

Client Feedback and Reputation

ABbiotek Health is regarded as a high-science, high-integrity partner in the functional ingredient space. Industry testimonials highlight the company's scientific rigor, formulation expertise, and regulatory support. Repeat collaborations with global supplement and functional beverage leaders reflect its growing reputation as a category pioneer.